AgingResearch.NewsJoin free

Revised Myeloma Comorbidity Index

There are 4 papers on Revised Myeloma Comorbidity Index in aging research: 1 trial and 3 observational studies in people.

Biomarker

4 papers study it4 more mention it1 finding

See all 8

“the 3-year OS rates were 90%, 74%, and 43% via the R-MCI for fit, intermediate-fit, and frail patients, respectively (P = .0006)”
Comparison of the prognostic significance of 5 comorbidity scores and 12 functional tests in a prospective multiple myeloma patient cohortCancer2021doi:10.1002/cncr.33658
  • Human trial1
  • Humans3

Associations

1

Mortality

upin humans1

1 study

  1. Revised Myeloma Comorbidity Index predicts mortality in humans (newly diagnosed multiple myeloma) (90% vs 74% vs 43% 3-year OS).

    “the 3-year OS rates were 90%, 74%, and 43% via the R-MCI for fit, intermediate-fit, and frail patients, respectively (P = .0006)”

    Humansnewly diagnosed multiple myeloman = 266

    Comparison of the prognostic significance of 5 comorbidity scores and 12 functional tests in a prospective multiple myeloma patient cohort

    Cancer

Latest

Related